NCT02339922 - Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 19, 2016

Primary Completion Date

December 30, 2024

Study Completion Date

January 6, 2031

Conditions

Chronic Lymphocytic LeukemiaFollicular LymphomaLymphoplasmacytic LymphomaMantle Cell LymphomaMarginal Zone LymphomaRecurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid TissueRefractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid TissueSmall Lymphocytic LymphomaWaldenstrom Macroglobulinemia

Interventions

DRUG

Ixazomib Citrate

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Rituximab

Given IV

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle